

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number  
WO 2004/041271 A1

(51) International Patent Classification<sup>7</sup>: A61K 31/4164,  
A61P 25/28 // A61K 9/08, 9/00

(21) International Application Number:  
PCT/FI2003/000850

(22) International Filing Date:  
10 November 2003 (10.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
20022007 8 November 2002 (08.11.2002) FI

(71) Applicant (for all designated States except US): OY JU-  
VANTIA PHARMA LTD [FI/FI]; Lemminkäisenkatu 5,  
FIN-20520 Turku (FI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): SAVOLA,  
Juha-Matti [FI/FI]; Siutlankatu 8, FIN-20380 Turku (FI).  
JUUKARVI, Päivi [FI/FI]; Ansakatu 10 B 8, FIN-20660  
Lieto (FI). ILKKA, Jukka [FI/FI]; Lohkaretie 14 as.  
7, FIN-70700 Kuopio (FI).

(74) Agent: TURUN PATENTTITOIMISTO OY; P.O. Box  
99, FIN-20521 Turku (FI).

(81) Designated States (national): AE, AG, AL, AM, AT (util-  
ity model), AU, AZ, BA, BB, BG, BR, BW, BY, BZ,  
CA, CH, CN, CO, CR, CU, CZ (utility model), DE,  
DK (utility model), DK, DM, DZ, EC,  
EE (utility model), EE, EG, ES, FI (utility model), FI, GB,  
GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,  
MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL,  
PT (utility model), PT, RO, RU, SC, SD, SE, SG, SK (util-  
ity model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG,  
US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW),  
ARIPO utility model (GH), ARIPO patent (GH), ARIPO

utility model (GM), ARIPO patent (GM), ARIPO utility  
model (KE), ARIPO patent (KE), ARIPO utility model  
(LS), ARIPO patent (LS), ARIPO utility model (MW),  
ARIPO patent (MW), ARIPO utility model (MZ), ARIPO  
patent (MZ), ARIPO utility model (SD), ARIPO patent  
(SD), ARIPO utility model (SL), ARIPO patent (SL),  
ARIPO utility model (SZ), ARIPO patent (SZ), ARIPO  
utility model (TZ), ARIPO patent (TZ), ARIPO utility  
model (UG), ARIPO patent (UG), ARIPO utility model  
(ZM), ARIPO patent (ZM), ARIPO utility model (ZW),  
ARIPO patent (ZW), Eurasian patent (AM, AZ, BY, KG,  
KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,  
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).


#### Declarations under Rule 4.17:

— as to the identity of the inventor (Rule 4.17(i)) for the fol-  
lowing designations AE, AG, AL, AM, AT, AU, AZ, BA, BB,  
BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE,  
DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,  
VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS,  
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,  
HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI  
patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,  
MR, NE, SN, TD, TG)

— as to the identity of the inventor (Rule 4.17(i)) for the fol-  
lowing designations AE, AG, AL, AM, AT, AU, AZ, BA, BB,  
BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE,  
DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC,  
VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS,  
MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent

[Continued on next page]

(54) Title: OROMUCOSAL FORMULATION AND PROCESS FOR PREPARING THE SAME



(I)

(57) Abstract: An oromucosal formulation comprising as an active ingredient a substituted imidazole derivative of formula (I) [please enter chemical formula here] where Y is -CH<sub>2</sub>- or -CO-, R<sub>1</sub> is halogen or hydroxy, R<sub>2</sub> is H or halogen and R<sub>3</sub> is H or lower alkyl, or an acid addition salt thereof, together with additives conventionally used in oromucosal formulations, and a process for its preparation.



(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG,

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

1/4 PS

10/534091


JCCS Rec'd PCT/PTO 06 MAY 2003

1

## OROMUCOSAL FORMULATION AND PROCESS FOR PREPARING THE SAME

### FIELD OF THE INVENTION

5           The present invention relates to an oromucosal formulation comprising as an active ingredient a substituted imidazole derivative of formula (I)



10

wherein Y is -CH<sub>2</sub>- or -CO-, R<sub>1</sub> is halogen or hydroxy, R<sub>2</sub> is H or halogen and R<sub>3</sub> is H or lower alkyl, or an acid addition salt thereof.

The invention also relates to a process for preparing the oromucosal formulation in question.

15

### BACKGROUND OF THE INVENTION

20           The compounds of the above-mentioned formula (I) are highly selective and long-acting antagonists of  $\alpha_2$ -adrenoceptors. The compounds are especially valuable in the treatment of cognitive disorders. Compounds of formula (I) and their preparation have been described in patent publication EP 0 618 906 B1. Specific examples of such compounds are 4-(2-ethyl-5-fluoroindan-2-yl)-1*H*-imidazole, i.e. fipamezole, and 4-(5-fluoroindan-2-yl)-1*H*-imidazole.

25           Although the compounds of formula (I) and their salts have good properties as such, they have disadvantages, when formulated for conventional oral administration, i.e. the normal route for administering said compounds. A problem is that the compounds rather quickly decompose in the gastrointestinal area or other body systems prior to accessing systemic blood flow and the therapeutic target organs. This in turn significantly lowers the  
30           effect of the compounds in question.

Toxicology studies carried out with dogs (see Example 8) have further suggested that cardiac safety considerations are of importance


whereas QT prolongation was observed with high oral doses of fipamezole when the systemic concentration of fipamezole reached about 2000 ng/ml.

## OBJECT AND SUMMARY OF THE INVENTION

5 One object of the present invention is to provide a formulation for administering compounds of formula (I) safely and efficiently.

Another object of the present invention is to provide a process for preparing the formulation.

Thus, according to one aspect of this invention concerns an  
10 oromucosal formulation comprising as an active ingredient a substituted imidazole derivative of formula (I)



15 where Y is  $-\text{CH}_2-$  or  $-\text{CO}-$ ,  $\text{R}_1$  is halogen or hydroxy,  $\text{R}_2$  is H or halogen and  $\text{R}_3$  is H or lower alkyl, or an acid addition salt thereof, together with additives conventionally used in oromucosal formulations.

According to another aspect, the invention concerns a process for preparing the oromucosal formulation.

20

## DETAILED DESCRIPTION OF THE INVENTION

It has now surprisingly been found that the problems of quick decomposition in the gastrointestinal area and compromised cardiac safety of the compounds of formula (I) can be alleviated by formulating the compounds  
25 of formula (I) into oromucosal formulations. Such formulations are effective and easy to handle, and therefore they have an advantage in terms of practical administration to the patient.

Suitable additives to be used in the formulation according to the present invention are adjuvants, expedients etc. including solvents, preserving  
30 agents, flavouring agents, fillers, gelling agents and mucoadhesive polymers. Preferred solvents are alcohols, especially ethanol, water and mixtures thereof. Preferred preserving agents are lower alkyl parahydroxybenzoates, especially methyl and propyl parahydroxybenzoate, and mixtures thereof. Preferred

flavouring agents are aspartame, artificial flavours, such as black currant 502.009, and mixtures thereof.

In this context, the oromucosal formulation means any type of formulation administered via oral mucosa. Such formulations include e.g. 5 sprays, gels, mucoadhesive buccal tablets and pastes, sublingual tablets and like. The formulation is preferably in the form of a spray.

In this context, the term *halogen* refers to F, Cl, Br and I, preferably to F and Cl and most preferably to F.

In this context, the term *lower alkyl* refers to a monoradical 10 branched or unbranched saturated hydrocarbon chain having from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms and most preferably 1 or 2 carbon atoms.

In this context, the term *an acid addition salt* refers to an addition salt of any pharmaceutically acceptable acid, preferably hydrochloric acid.

15 In this context, the term *an additive conventionally used in oromucosal formulations* refers to any additive known by the person skilled in the art to be applicable for oromucosal formulations.

An especially preferred active ingredient is fipamezole (JP-1730, 4-(2-ethyl-5-fluoroindan-2-yl)-1*H*-imidazole hydrochloride). A formulation 20 containing said preferred active ingredient is prepared according to the invention by mixing and dissolving ethanol (96%), purified water, methylparahydroxybenzoate, propylparahydroxybenzoate and aspartame at room temperature, at +15 to +25 °C. Followed by adding and dissolving 4-(2-ethyl-5-fluoroindan-2-yl)-1*H*-imidazole and artificial flavour, such as black 25 currant 502.009A, at room temperature, at +15 to +25 °C. The volume of the mixture is adjusted with purified water, followed by filtering and the desired spray formulation is recovered.

The following examples illustrate the invention, but are not intended to restrict the scope of the invention.

**Example 1**

**Spray formulation containing 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole hydrochloride (fipamezole)**

5 **Fipamezole oromucosal spray**

<b>Ingredient</b>	<b>Quantity per 1 ml</b>	<b>Function</b>
Fipamezole	15.0 mg	Active
Methyl parahydroxybenzoate	1.8 mg	Preservative
Propyl parahydroxybenzoate	0.2 mg	Preservative
Aspartame	0.5 mg	Flavouring agent
Artificial flavour*	0.4 mg	Flavouring agent
Ethanol (96 %)	0.416 ml	Solvent
Purified water	ad 1.0 ml	Solvent

\*Artificial flavour, such as black currant 502.009A, for example, but not restricted to.

10

**Example 2**

**Spray formulation containing 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole hydrochloride (fipamezole)**

Fipamezole oromucosal spray

15

<b>Ingredient</b>	<b>Quantity per 1 ml</b>	<b>Function</b>
Fipamezole	161.0 mg	Active
Methyl parahydroxybenzoate	1.8 mg	Preservative
Propyl parahydroxybenzoate	0.2 mg	Preservative
Aspartame	0.5 mg	Flavouring agent
Artificial flavour*	0.4 mg	Flavouring agent
Ethanol (96 %)	0.416 ml	Solvent
Purified water	ad 1.0 ml	Solvent

\*Artificial flavour, such as black currant 502.009A, for example, but not restricted to.

**Example 3****Preparation of a spray formulation containing 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole hydrochloride (fipamezole)**

5            416.0 ml of ethanol (96 %) was mixed with 450.0 ml of purified water to form a homogenous mixture. 1.80 g of methylparahydroxybenzoate, 0.20 g of propylparahydroxybenzoate and 0.5 g of aspartame were added to the mixture and dissolved at room temperature, at +15 to +25 °C. 15.0 g of fipamezole, 0.4 g of black currant flavour were added to the mixture and  
 10 dissolved at room temperature, at +15 to +25 °C. The volume of the mixture was adjusted to 1000.0 ml with purified water. The solution was filtered and the desired spray formulation was recovered.

**Example 4**

15            **Preparation of an oromucosal gel formulation containing 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole hydrochloride (fipamezole) 30 mg**

**Composition**

<b>Ingredient</b>		<b>Amount/single dose</b>
1	Fipamezole	30 mg
2	Ethanol (96 %)	250 mg
3	Poloxamer 407	200 mg
4	Liquid flavour (artificial)	0.5 mg
5	Aspartame (sweetener)	0.5 mg
6	Purified water	519 mg
Total of		1000 mg

20

**Method of preparation**

Fipamezole (1) and ethanol (96 %) (2) are mixed and dissolved to form a solution A. Purified water (6), poloxamer 407 (3), liquid flavour (4), and aspartame (5) are mixed and dissolved to form a solution B. Solution A and

solution B are cooled down to approx. +5 °C, and mixed together to form a homogenous solution. Oromucosal gel formulation is recovered.

### Example 5

- 5            **Preparation of a mucoadhesive buccal tablet formulation containing 4-(2-ethyl-5-fluoroindan-2-yl)-1*H*-imidazole hydrochloride (fipamezole) 30 mg**

#### Composition

Ingredient		Amount/single dose
1	Fipamezole	30 mg
2	Carbomer 934P	12.35 mg
3	Hydroxypropylmethylcellulose	49.4 mg
4	Flavour (artificial)	4 mg
5	Aspartame (sweetener)	4 mg
6	Magnesium stearate	0.25 mg
Total of		100 mg

10

#### Method of preparation

- Fipamezole (1), carbomer 934P (2), hydroxypropylmethylcellulose (3), flavour (4), aspartame (5), and magnesium stearate (6) are mixed to form a homogenous mixture. The mixture is compressed to tablets of a suitable size. Mucoadhesive buccal tablets are recovered.
- 15



**Example 6**

**Preparation of a sublingual tablet formulation containing 4-(2-ethyl-5-fluoroindan-2-yl)-1*H*-imidazole hydrochloride (fipamezole) 30 mg**

5

**Composition**

<b>Ingredient</b>		<b>Amount/single dose</b>
1	Fipamezole	30 mg
2	Lactose monohydrate	30 mg
3	Povidone	2.4 mg
4	Microcrystalline cellulose	10.8 mg
5	Flavour	3.2 mg
6	Aspartame (sweetener)	3.2 mg
7	Magnesium stearate	0.4 mg
Total of		80 mg

**Method of preparation**

Fipamezole (1), lactose monohydrate (2), flavour (5), and  
 10 aspartame (6) are mixed to form a homogenous mixture. The mixture is  
 granulated with 10 % aqueous solution of povidone (3). Granules are formed in  
 either high-shear or low-shear mixer. Granulated mixture is let to dry. Dry,  
 granulated mixture is passed through a screen to obtain freely flowing  
 granulate. Microcrystalline cellulose (4) and magnesium stearate (7) are mixed  
 15 with the granulate. The final blend is compressed to tablets of a suitable size.  
 Sublingual tablets are recovered.

**Example 7**

20

**Oromucosal delivery of fipamezole**

Plasma levels of fipamezole were studied in healthy male volunteers  
 after oral administration of the drug as a solution. Blood samples for  
 pharmacokinetic evaluation were collected for 24 hours after the drug

administration. The concentration of fipamezole in plasma was measured with HPLC-MS/MS, and the pharmacokinetic parameters were calculated. The pharmacokinetics of fipamezole was evaluated with TopFit 2.0 pharmacokinetic program. The  $C_{max}$  and  $t_{max}$  values were read from the concentration vs. time curves, and the apparent elimination phase half-lives from the terminal part of the semilogarithmic concentration vs. time curve (see Figure 1). AUC values were calculated both to infinity and up to the last collection time with quantifiable fipamezole concentration. The results are given in Table 1.

10

Table 1. Mean (SD) pharmacokinetic parameters of fipamezole at the dose level of 30 mg.  $t_{max}$  values are given as median and range.

30-mg dosing	$C_{max}$ (ng/ml)	$t_{max}$ (h) <sup>a</sup>	$t_{1/2el}$ (h)	$AUC_{0-inf}$ (ng*h/ml)
Oral	1.59 (0.38)	1.0 (0.75-2.0)	3.10 (2.23)	7.65 (2.99)
Oromucosal, tablet	31.74 (13.50)	0.85 (0.43)	3.10 (1.00)	115.6 (41.10)
Oromucosal, spray	49.2 (11.0)	0.7 (0.5-1.0)	2.10 (0.20)	157.1 (24.7)

$C_{max}$ , maximal drug concentration in serum;  $t_{max}$ , time of maximal drug concentration in serum;  $t_{1/2el}$ , apparent elimination phase half-life;  $AUC_{0-inf}$ , area under the drug concentration in serum vs. time curve from time 0 to infinity.

Mean plasma concentration time plot following single dose administration of 30 mg fipamezole via an oral, oromucosal spray and an oromucosal tablet on a semilogarithmic scale is shown in Figure 1.

20

**Example 8****Cardiac safety**

Cardiac safety was studied in dogs in a 30-day dog toxicology study using oral dosing and dog toxicology studies using buccal dosing.

5           In the 30-day dog toxicology study fipamezole was administered orally at doses of 1, 5, 10 and 15 mg/kg/day for 30 days, resulting in maximum systemic fipamezole concentrations of about 200, 1000, 2000 and 3300 ng/ml, respectively. These in vivo results in the dog suggested that QT prolongation was observed when the systemic concentration of fipamezole reached about  
10   2000 ng/ml.


          In another toxicology study four male dogs were given fipamezole in buccal spray doses of 1, 5 and 10 mg/kg in a sequential dosing regimen with 5 to 15 days between doses. Blood pressure (systolic, diastolic and mean), heart rate and ECGs were monitored before and up to 12 hours after dosing. At 30  
15   minutes after dosing with 5 and 10 mg/kg significant transient increases in absolute values for blood pressure and heart rate were observed. No ECG changes (P wave amplitude, P wave duration, P-Q interval, QRS interval or Q-T [Q-Tcv, QTc] interval) were apparent after fipamezole dosing at each dose level.

20           Yet another toxicology study using buccal delivery to dogs at dose levels of 1, 5 and 10 mg/kg/day for up to 4 weeks showed no apparent changes in ECG. Maximum systemic concentrations of fipamezole after dosing on the first day of this study were about 800, 2000 and 3300 ng/ml.

## Claims

1. An oromucosal formulation comprising as an active ingredient a substituted imidazole derivative of formula (I)

5



where Y is -CH<sub>2</sub>- or -CO-, R<sub>1</sub> is halogen or hydroxy, R<sub>2</sub> is H or halogen and R<sub>3</sub> is H or lower alkyl, or an acid addition salt thereof, together with additives conventionally used in oromucosal formulations.

10

2. A formulation according to claim 1 wherein the active ingredient is 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole or its acid salt, preferably hydrochloride.

15

3. A formulation according to claim 1 or 2 wherein the additives are selected from solvents, preserving agents, flavouring agents and mixtures thereof.

20

4. A formulation according to claim 3 wherein the solvent is selected from ethanol, water and a mixture thereof.

5. A formulation according to claim 3 or 4 wherein the preserving agent is selected from methyl parahydroxybenzoate, propyl parahydroxybenzoate and a mixture thereof.

25

6. A formulation according to any of claims 3 to 5 wherein the flavouring agent is selected from aspartame, black currant and a mixture thereof.

7. A formulation according to claim 1 comprising the following components: (a) 4-(2-ethyl-5-fluoro-indan-2-yl)-1H-imidazole or its acid salt, preferably hydrochloride, (b) ethanol and water, (c) methyl parahydroxybenzoate and propyl parahydroxybenzoate, and (d) aspartame and black currant.


8. A formulation according to any of the preceding claims wherein the formulation is in the form of a spray, gel, a mucoadhesive buccal tablet or paste, or a sublingual tablet.

9. A formulation according to claim 8 wherein the formulation is in the form of a spray.

10. A process for preparing a formulation according to claim 7 comprising mixing and dissolving ethanol (96 %), purified water, methyl parahydroxybenzoate, propyl parahydroxybenzoate and aspartame at room temperature, at +15 to +25 °C; followed by adding and dissolving 4-(2-ethyl-5-fluoroindan-2-yl)-1H-imidazole hydrochloride and artificial flavour, preferably black currant 502.009A, at room temperature, at +15 to +25 °C; adjusting the volume of the mixture with purified water, followed by filtering and recovering the desired spray formulation.

## (57) Abstract

An oromucosal formulation comprising as an active ingredient a substituted imidazole derivative of formula (I)



5

where Y is -CH<sub>2</sub>- or -CO-, R<sub>1</sub> is halogen or hydroxy, R<sub>2</sub> is H or halogen and R<sub>3</sub> is H or lower alkyl, or an acid addition salt thereof, together with additives conventionally used in oromucosal formulations, and a process for its preparation.

10





Figure 1